pharma · Not applicable, healthy volunteers · ulcerative pyoderma gangrenosum
InflaRx
InflaRx GmbH
InflaRx is a pharma organization headquartered in Jena, DE. Primary therapeutic focus areas include Not applicable, healthy volunteers, ulcerative pyoderma gangrenosum. NovaPharmaNews links 4 clinical program(s), 0 drug
Jena, DE HQ
2007 Founded
52 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Jena, DE
- Founded
- 2007
- Employees
- 52
- Programs
- 4
- Drugs
- 20
- Patents
- 0
INF904
Phase 2 · small molecule · Moderate to Severe Chronic Spontaneous Urticaria (CSU) or Moderate to Severe Hidradenitis Suppurativa (HS)
INF904 for Moderate to Severe Chronic Spontaneous Urticaria (CSU) or Moderate to Severe Hidradenitis Suppurativa (HS) is a Phase 2 program (small_molecule) at InflaRx GmbH with 1 ClinicalTrials.gov record(s).
Internal code INF904-P2.1
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- InflaRx GmbH
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Moderate to Severe Chronic Spontaneous Urticaria (CSU) or Moderate to Severe Hidradenitis Suppurativa (HS)
- Status
- active
- Trials
- 1